• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad , Dec. 9

NATCO Pharma Ltd has announced the launch of its drug for multiple myeloma (a form of blood cancer) under the brand `Alphalan' (Melphalan) in 2 mg and 5 mg tablet forms.

In a press release here on Thursday, the company said the launch of Alphalan would mark the introduction of the niche product to India. The company said Alphalan is the only Indian product available in the market for the treatment of multiple myeloma. According to the company, multiple myeloma affects the plasma cell, which is an important part of the immune system. In the case of persons affected with this disease, the malignant plasma cells accumulate and damage the bone marrow in the spine, pelvis, rib cage and the skull. Rated as the second most prevalent form of blood cancer, multiple myeloma ( is responsible for two per cent of all cancer deaths, the company said.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

More Stories on : Announcements | New Products & Services

Stories in this Section
SAIL board okays plan to upgrade RSP facilities

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line